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 Atherosclerotic plaque rupture is a leading cause of 
acute coronary syndromes, such as unstable angina and 
myocardial infarction ( 1 ). Infl ammatory cells are regarded 
as key players in the pathogenesis of plaque rupture ( 2, 3 ), 
and the mast cell, a potent infl ammatory cell, has been 
shown to accumulate in the rupture-prone shoulder re-
gion of human atheromas ( 4 ). Activated mast cells have 
been identifi ed in the adventitia of vulnerable and rup-
tured lesions in patients with myocardial infarction, and 
more importantly, their numbers and degree of activation 
were found to correlate with the incidence of plaque rup-
ture and erosion ( 5 ). We previously demonstrated that sys-
temic mast cell activation during atherogenesis leads to 
increased plaque progression in apoE defi cient mice ( 6 ), 
while others show that the absence of mast cells, and in 
particular mast cell-derived interleukin (IL)-6 and in-
terferon (IFN)-  , attenuated atherosclerotic lesion devel-
opment in low-density lipoprotein receptor-deficient 
(LDLr   /   ) mice ( 7 ). Moreover, focal activation of mast 
cells in the adventitia of advanced carotid artery plaques 
promoted macrophage apoptosis, microvascular leakage, 
de novo leukocyte infl ux, and the incidence of intraplaque 
hemorrhage. Mast cell stabilization by cromolyn was seen 
to prevent these pathophysiological events ( 6 ). 
 Various pathways of mast cell activation have been 
demonstrated such as cross-linking of the high-affi nity 
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Hereto, mice were sacrifi ced by perfusion through the left 
cardiac ventricle with phosphate-buffered saline (150 mM NaCl, 
1.5 mM NaH 2 PO 4 , 8.6 mM Na 2 HPO 4 , pH 7.4) followed by perfu-
sion with 128 mM ammonium bicarbonate to remove salts which 
interfere with secondary ion mass spectrometry (SIMS) measure-
ments. Subsequently, the common carotid arteries were both 
excised, embedded in 10% gelatin at 30°C and snap-frozen in 
liquid nitrogen for optimal lipid preservation. 
 Transverse 10 µm cryosections were prepared on a Leica CM 
3050 cryostat (Leica Microsytems, Rijswijk, The Netherlands) at 
  20°C. The sections were cut in a proximal direction from the 
carotid bifurcation and mounted in order on a parallel series of 
glass slides, alternating between 1% gelatin-coated slides for im-
munohistological staining and conductive transparent indium tin 
oxide-coated slides (Delta Technologies, Stillwater, MN) for time-
of-fl ight (TOF)-SIMS, which are stored at   80°C until further use. 
The sample surface of a series of sections mounted on conductive 
slides were sputter coated with gold using a Quorum Technologies 
(Newhaven, East Sussex, UK) SC7640 sputter coater. 
 All static SIMS experiments were performed on a Physical 
Electronics (Eden Prairie, MN) TRIFT-II TOF-SIMS instrument 
described elsewhere ( 26 ) and newly equipped with a gold liquid 
metal ion gun. Secondary ions were extracted through a 3.2 keV 
electric fi eld into the TOF analyzer and postaccelerated by an 
additional 8 keV fi eld prior to detection on a dual multichannel 
plate/phosphor screen detector. All experiments were per-
formed with a primary ion beam current of 1 nA, a primary pulse 
length of 18 ns, and a primary ion energy of 22 keV. The ion dose 
was such that all analyses were conducted at or under the static 
SIMS threshold (10 13 ions/cm 2 ) for reduced fragmentation of ana-
lytes. The instrument was calibrated in both positive and negative 
mode on high-occurrence elements and fragments such as H +/   , 
CH n 
+ , Na + , K + , O    , and OH    . To ensure correct identifi cation of the 
lipid species of interest, reference samples of 18:1/18:1 PA, 18:1 
LPA, and S1P were analyzed with SIMS and matrix-enhanced  SIMS. 
 Cell culture 
 The capacity of LPA to activate murine mast cells was studied 
on MC/9 mast cells as well as on freshly isolated peritoneal mast 
cells (PMCs). MC/9 cells were cultured as described previously ( 6 ). 
Bone marrow-derived mast cells (BMMCs) were cultured by cul-
turing bone marrow cells at a density of 0.25 × 10 6 cells in RPMI 
containing 10% fetal bovine serum (FBS), 2 mmol/l  L -glutamine , 
100 U/ml penicillin, 100   g/ml streptomycin, and murine IL3 for 
4 weeks. Total RNA was extracted from these cells with guanidine 
thiocyanate , reverse transcribed using M-MuLV reverse transcriptase 
(RevertAid, MBI Fermentas, Leon-Roth, Germany) and expression 
of target genes was measured by quantitative PCR on an ABI PRISM 
7500 Taqman apparatus (Applied Biosystems, Foster City, CA). 
 PMCs from C57Bl/6 mice were isolated by lavage of the peri-
toneal cavity with 10 ml of ice-cold PBS. Cells were seeded at 2 × 
10 6 cells/ml in RPMI containing 10% fetal bovine serum (FBS), 
2 mmol/l  L -glutamine, 100 U/ml penicillin, 100   g/ml streptomy-
cin, and murine IL3 and allowed to attach for 1 h. Nonadhered cells 
were seeded at 2.5 × 10 5 cells/ml and used for degranulation 
experiments. MC/9 cells, BMMCs, and PMCs (2.5 × 10 5 cells) 
were activated by incubation with compound 48/80 (0.5   g/ml, 
Sigma, Zwijndrecht, The Netherlands) or 10 µg/ml LPA (22 µmol/l, 
18:1, Sigma) (n = 3 per condition) for 30 min at 37°C in HEPES-
tyrode supplemented with 0.1% fatty acid-free BSA (BSA, Sigma). 
Cells were centrifuged (1,500 rpm, 5 min) and the releasate was 
used for further experiments. For total (100%) release measure-
ments, mast cells were lysed with 10% Triton X-100 and untreated 
control cell supernatant served as 0% release control. In vivo 
mast cell activation was determined in C57Bl/6 mice and mast cell 
defi cient Kit(W   sh /W   sh ) mice that had received intraperitoneal 
IgE receptor by multiple IgE molecules ( 8 ), neurogenic 
stimulation ( 8, 9 ), infl ammatory stimuli (e.g., tumor ne-
crosis factor   and IL-1), and complement factors (e.g., 
C3a and C5a) ( 10 ). Although the endogenous triggers 
for mast cell activation in atherosclerosis are still un-
known, IgE ( 11 ), IgG-oxidized low-density lipoprotein 
(oxLDL) immune complexes ( 12 ), the neuropeptide 
substance P ( 9, 13 ), and the complement system ( 14 ) 
were suggested to activate mast cells in atherosclerosis. 
Furthermore, oxLDL itself was seen to promote mast cell 
activation ( 15, 16 ). Lysophosphatidic acid (LPA), a bio-
active lipid and major constituent of modified LDL, 
may be a potential candidate in this regard, as mast cells 
express several LPA receptors ( 17 ) through which LPA 
can affect mast cell function. Indeed, Bagga et al. dem-
onstrated that LPA accelerates human mast cell prolif-
eration and differentiation via LPA 1/3 - and peroxisome 
proliferator-activated receptor   -dependent pathways ( 18 ). 
In addition, LPA triggers the release of a wide range of pro-
infl ammatory chemokines such as macro phage infl amma-
tory protein-1  , IL-8, eotaxin, and monocyte chemoattractant 
protein (MCP)-1, which can attract infl ammatory cells to the 
arterial wall ( 19 ). It is worth noting that LPA progressively 
accumulates in human and mouse atherosclerotic plaques 
( 20, 21 ), and was shown to be involved in atherogenesis by 
virtue of its pro-coagulating capacity ( 20, 22 ) and its endothe-
lial/leukocyte inter action ( 23, 24 ). 
 In this study, we have therefore investigated the poten-
tial involvement of LPA in mast cell-driven plaque destabi-
lization. We demonstrate that LPA can activate adventitial 
mast cells, promote monocyte recruitment and microvas-
cular leakage, and lead to an enhanced incidence of intra-
plaque hemorrhage. Finally, our data indicate that the 
adverse events of LPA-induced mast cell activation can be 
largely inhibited by the mast cell stabilizer cromolyn. 
 METHODS 
 Animals 
 All animal work was performed in compliance with the 
Dutch government guidelines and conducted in conformity 
with the Health Service Policy (PHS) on Humane Care and 
Use of Laboratory Animals. C57Bl/6 mice (Charles River, 
Maastricht, The Netherlands) and mast cell defi cient Kit(W   sh /
W   sh ) mice (Jackson Laboratories) were maintained in the 
local animal breeding facility. Male LDLr   /   mice, apolipopro-
tein E-defi cient (apoE   /   ) mice, and apoE   /   Kit(W   sh /W   sh ) 
mice were fed a Western-type diet containing 0.25% choles-
terol and 15% cacaobutter (SDS, Sussex, UK). Atherosclerotic 
carotid artery lesion formation was induced by perivascular 
collar placement as described previously ( 25 ). Mice were anes-
thetized by subcutaneous injection of ketamine (60 mg/kg, 
Eurovet Animal Health, Bladel, The Netherlands), fentanyl 
citrate, and fl uanisone (1.26 mg/kg and 2 mg/kg respectively, 
VetaPharma Ltd, Leeds, UK). 
 MS imaging 
 Lipid distribution of carotid artery plaques in LDLr   /   mice 
was determined at 9 weeks after perivascular collar placement. 
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 Histology 
 Mast cells were visualized by staining of 5   m cryosections with 
aqueous Toluidine blue (Sigma). Neutrophils were stained with 
naphthol AS-D chloroacetate esterase (Sigma). Iron staining was 
performed according to Perl’s method. Monocytes/macrophages 
were stained immunohistochemically with monocyte/macrophage 
antibody-2 (MOMA-2) (monoclonal mouse IgG2a, dilution 1:50; 
Serotec, Kidlington, Oxford, UK ). Apoptosis was visualized using 
a terminal deoxytransferase dUTP nick-end labeling (TUNEL) 
kit (Roche Diagnostics). Morphometric analysis (Leica QWin 
image analysis software) was performed on hematoxylin-eosin 
stained sections of the carotid arteries at the site of maximal 
stenosis. Toluidine blue-stained sections were used for histologi-
cal examination for the presence of perivascular mast cells. Neu-
trophil numbers, mast cell numbers, the extent of mast cell 
degranulation, and the presence of iron were assessed manually. 
A mast cell was considered resting when all granula were main-
tained inside the cell, while mast cells were assessed as activated 
when granula were deposited in the tissue surrounding the mast 
cell. MOMA-2 and TUNEL-positive areas were quantifi ed with 
Leica QWin image analysis software and, in addition, TUNEL-
positive nuclei were counted manually. All morphometric analy-
ses were performed by blinded independent operators. 
 Statistical analysis 
 Data are expressed as mean ± SEM. A two-tailed Student’s  t -test 
was used to compare individual groups. Non-Gaussian distrib-
uted data were analyzed using a Mann-Whitney U test. Frequency 
data analysis was performed by means of the Fisher’s exact test. 
A level of  P < 0.05 was considered signifi cant. 
 RESULTS 
 MS imaging 
 We have applied imaging mass spectrometry via TOF-
SIMS for verifi cation and high-resolution spatial localiza-
tion of lipids in carotid artery lesions from LDLr   /   mice. 
SIMS analysis shows strong signals for inorganic ions and 
ionized organic compounds derived from fragmentation 
of surface molecules. A number of LPA species could be 
detected in plaque material, and were tentatively assigned 
on the basis of their M+ peak ( Fig. 1A ). Flanking sections 
were stained for hematoxylin-eosin and macrophage con-
tent ( Fig. 1B, C ) to correlate intraplaque lipid distribu-
tion profi les to morphological features. Color intensity 
of the ion micrographs corresponded to signal strength 
( Fig. 1D ). Assessment of the intraplaque distribution of 
these lipids was performed on the basis of their intact mass 
anions [M-H]    , as determined by LC/MS of crude plaque 
lipid pools: 14:0 LPA ( m/z 381), 16:0 LPA ( m/z 409), 16:1 
LPA ( m/z 407), 18:0 LPA ( m/z 437), 18:1 LPA ( m/z 435), 
18:2 LPA ( m/z 433), 18:3 LPA ( m/z 431), 20:2 LPA ( m/z 
459), 20:3 LPA ( m/z 457), 22:4 LPA ( m/z 481), and 22:5 
LPA ( m/z 479). We were able to detect not only LPA iso-
forms 16:0, 16:1, 18:0, 18:1, 18:2 and 18:3, but also 20:2, 
20:3, 22:4, and 22:5 in the atherosclerotic plaque . The 
individual LPA species show a similar distribution pattern 
as cholesterol, phosphatidic acids, and triglycerides ( Fig. 
1E, F ), with the most pronounced accumulation in the 
noncellular core region of the plaque. Thus LPA species, 
injections of LPA (1.75 µg) or PBS (n = 4 per group). At baseline 
and at 2 h after injection, the releasate was collected by fl ushing 
the peritoneal cavity with ice-cold PBS. 
  -Hexosaminidase activity was determined by adding 50   l of 
releasate to 50   l 2 mM 4-nitrophenyl  N -acetyl-b-D-glucosamin-
ide (Sigma) in 0.2 M citrate (pH 4.5) and incubated at 37°C for 
2 h. After addition of 150   l 1 M Tris (pH 9.0), absorbance (opti-
cal density) was measured at 405 nm (OD405). To measure chy-
mase and tryptase release after degranulation, 50   l supernatant 
was added to 2 mM S-2288 (tryptase substrate, Chromogenix, Lex-
ington, MA) or S-2586 (chymase substrate, Chromogenix) in PBS 
supplemented with 100 U/ml heparin. After 2 h (tryptase) or 24 h 
(chymase) at 37°C, OD405 was measured. Values are expressed 
as percentage of total release. MCP-1 levels were determined 
by ELISA according to the manufacturer’s protocol (eBioscience). 
 RAW 264.7 macrophage cells were cultured in Dulbecco’s modi-
fi ed Eagle medium (DMEM) containing 10% FBS, 2 mmol/l 
 L -glutamine, 100 U/ml penicillin, and 100   g/ml streptomycin. 
For proliferation experiments cells were seeded in 24-well dishes at 
a density of 1 × 10 5 cells/ml in DMEM containing 1% FBS, 
2 mmol/l  L -glutamine, 100 U/ml penicillin, and 100   g/ml strep-
tomycin for 24 h to synchronize cell cycle. Subsequently, fresh se-
rum-free DMEM containing 0.2% BSA and 18:1 LPA at various 
concentrations was added to the cells and cultured for 40 h with-
out medium change. Ten percent FBS in DMEM was used as a posi-
tive control. After 16 h [ 3 H]thymidin (5.0 µCi/well; GE Healthcare, 
Eindhoven, The Netherlands) was added and cells were incubated 
further for 24 h . Thereafter, cells were washed three times with 
PBS, lysed with 0.1 mol/l NaOH, and cell-associated radioactivity 
was determined by liquid scintillation counting. 
 Cellular apoptosis was measured after overnight treatment of 
RAW 264.7 macrophages with tryptase (10 ng/ml, Sigma) in the 
presence or absence of LPA (22 µmol/l, 10 µg/ml). Cells were 
collected and stained with Annexin V/PI after which the percent-
age of cell death was measured using fl ow cytometry. 
 Microvascular leakage 
 Microvascular permeability was assessed as previously described 
( 6 ). In short, male C57Bl/6 mice were injected intradermally at 
randomized sites with 5 × 10 5 MC/9 mast cells suspended in PBS 
containing 50   g/ml compound 48/80 or 18:1 LPA (10 µg/ml) 
(n = 6 per group). Immediately after intradermal injection of the 
cell suspensions, 100   l 1.25% Evans Blue was injected intrave-
nously and after 30 min the surface area of Evans Blue-stained 
skin was measured. To measure MC/9 activation in skin, MC/9 
cells using the conditions as described above were randomly in-
jected intradermally in mast cell defi cient Kit(W   sh /W   sh ) mice, 
which lack endogenous skin mast cells. After 30 min, skin spots 
were excised and embedded in OCT compound for cryosection-
ing. Sections 10 µm thick were routinely stained with Alcian 
Blue/Safranin O (Sigma) and mast cell activation status was 
scored manually. 
 Local LPA challenge 
 Six weeks after collar placement, when advanced atheroscle-
rotic lesions had developed, apoE   /   or apoE   /   Kit(W   sh /W   sh ) 
mice were challenged perivascularly by applying pluronic F-127 
gel (25% w/v) or pluronic F-127 gel containing LPA (20   mol/l, 
  92 ng/animal) proximal to the collar (n = 8–12 per group). 
A subset of the LPA-challenged animals received an intravenous 
injection of the mast cell stabilizer cromolyn (25 mg/kg, Sigma) ( 6 ) 
thirty minutes before and twice daily after local challenge (50 mg/
kg ip). Three days after LPA-challenge mice were anesthetized and 
in situ fi xation through the left cardiac ventricle was performed, after 
which the carotid artery lesions were excised for further analysis . 
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 Mast cell releasate 
 To determine whether LPA has the capacity to activate 
mast cells, releasates of compound 48/80 and LPA stimu-
lated MC/9 cells, BMMCs, and freshly isolated peritoneal 
mast cells were analyzed. Supernatants of untreated mast 
cells were used as negative controls (0% release), while 
cell lysates of untreated cells were used for total mast cell 
content analysis (100%). Both compound 48/80 and LPA 
were able to induce release of   -hexosaminidase activity 
and tryptase from MC/9 cells.   -Hexosaminidase activity 
in the releasate of compound 48/80 and LPA stimulated 
MC/9 cells did not differ (3.1 ± 0.8% vs. 5.7 ± 1.5% of total 
release, respectively). Interestingly, tryptase release was much 
including 18:1, the biologically most potent isoform and 
one of the most abundant LPA species ( 21 ) (supplemen-
tary Fig. I), are abundantly present in the atherosclerotic 
plaque, in particular in the necrotic core. The LPA as-
signed peaks detected in SIMS imaging analysis of plaque 
lysates are identical to  m/z values obtained by LC/MS 
spectroscopy, thus providing an orthogonal validation 
of the SIMS results. Further analysis of the identifi ed 
LPA peaks using the database provided by the group of 
Brunelle ( 27 ) shows a lack of overlap of the most typical 
fragments with DAG-H 2 O and free fatty acid peaks, mak-
ing it unlikely that the former result from phospholipid 
fragmentation. 
 Fig.  1. A: TOF-SIMS spectra recorded from an atherosclerotic artery segment in negative mode with tenta-
tive peak assignments, showing LPA species. B: HE staining and C: MOMA-2 + macrophage staining of a 
mouse carotid artery lesion. Negative ion micrographs of a fl anking lesion analyzed by TOF-SIMS. Color 
intensity corresponds to signal strength . D: Total ion current (TIC). E: Intraplaque distribution patterns 
of a selection of relevant ions including phosphatidic acids, triglycerides, and cholesterol. F: Several LPA 
species. Scale bar indicates 100 µm. 
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that LPA 1 was the main LPA receptor expressed by our 
murine mast cell cultures (supplementary Fig. III), while 
LPA 2 and LPA 3 were undetectable. LPA 1 expression was 
highest in BMMCs that were skewed toward a connective 
tissue type mast cell, the predominant phenotype in the 
vessel wall ( 6 ). 
 In peritoneal mast cells, LPA induced   -hexosaminidase 
activity (7.0 ± 1.2% as compared with 9.1 ± 3.6% for 48/80). 
LPA again robustly increased tryptase release (19.3 ± 7.0% 
of total release), while compound 48/80 had only mar-
ginal effects (3.0 ± 0.3% of total release). In line with these 
data, after intraperitoneal LPA challenge tryptase activity 
in the supernatant was increased by 2.3-fold in C57Bl/6 
but not in mast cell-defi cient Kit(W   sh /W   sh ) mice ( P < 0.05, 
 Fig. 2A ). While we did not observe signifi cant differences 
in the activity of chymase [PBS: 1.0 ± 0.04 vs. LPA: 1.00 ± 0.04 
higher after LPA stimulation (4.7 ± 1.0% of the total pool 
was released vs. undetectable levels for compound 48/80). 
In line with these data, LPA induced   -hexosaminidase 
activity (9 ± 1%) as well as tryptase activity (6 ± 1%) in the 
releasate of BMMCs. The LPA 1 receptor antagonist Ki16245 
inhibited   -hexosaminidase and tryptase release from 
MC/9 cells and BMMCs (supplementary Fig. IIA, B), sug-
gesting that LPA mediates mast cell activation mainly via 
LPA 1 . LPA was also seen to induce MCP-1 release from 
MC/9 cells (46 ± 6 pg/ml, supplementary Fig. IIC), which 
was at least partly inhibitable by Ki16245 (17 ± 10 pg/ml, 
 P < 0.05 compared with LPA). Interestingly, compound 
48/80 did not induce MCP-1 release, suggesting that this 
effect is LPA-specifi c. 
 The involvement of LPA 1 in LPA-mediated mast cell ac-
tivation was further confi rmed by our PCR data, establishing 
 Fig.  2. LPA induces tryptase release from mast cells and induces vascular leakage. A: After intraperitoneal 
LPA challenge tryptase activity was increased by 2.3-fold in the C57Bl/6 mice, which did not occur in mast 
cell defi cient Kit(W   sh /W   sh ) mice. * P < 0.05 compared with C57Bl/6 at baseline. B: LPA, compound 48/80, 
and nonactivated MC/9 cells induced minor to moderate vascular leakage as judged by Evans Blue spot size, 
probably due to activation of locally residing mast cells. LPA-activated MC/9 cells signifi cantly induced vas-
cular leakage, similarly as compound 48/80-activated MC/9 cells, which were used as positive control. ** P < 
0.01, *** P < 0.001 compared with PBS control,  # P < 0.05,  ## P < 0.01 compared with MC/9. C: Quantifi cation 
of activated MC/9 cells in skins of mast cell defi cient Kit(W   sh /W   sh ) mice, illustrating the mast cell absence 
in PBS, compound 48/80, and LPA injected skins. Injection of unstimulated MC/9 cells resulted in sponta-
neous activation of 47 ± 6% possibly due to shear stress, a number that was signifi cantly increased by prior 
mast cell priming with compound 48/80 and LPA.  # P < 0.05,  ## P < 0.01 compared with unstimulated MC/9 
cells. 
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plaque. We have also fi rmly established that LPA is 
a potent mast cell activator. To assess a functional role of 
LPA in adventitial mast cell activity and plaque progres-
sion in vivo, LPA (18:1) was applied perivascularly through 
a pluronic F-127 gel at the collar-induced carotid artery 
lesion in apoE   /   mice. As expected, morphometric analy-
sis of the carotid lesions 3 days after challenge did not re-
veal any differences in plaque size between control and 
LPA-challenged animals (92 ± 13 × 10 3   m 2 vs. 96 ± 110 × 
10 3   m 2 respectively,  Fig. 3A ). Treatment with the mast 
cell stabilizer cromolyn for 3 days did not affect plaque size 
as well (93 ± 10 × 10 3   m 2 ). Additionally, no differences 
were found in medial surface area and percentage of 
artery stenosis (data not shown). 
 The number of adventitial mast cells as determined by 
toluidine blue staining did not differ between LPA- and 
mock-challenged mice ( Fig. 3B ), but the percentage of de-
granulated perivascular mast cells was still increased at 
time of sacrifi ce (three days after LPA stimulation, 53 ± 6% 
vs. 36 ± 7% activated mast cells in control animals,  P = 0.04, 
 Fig. 3C ). As mast cell activation occurs very acutely after 
application of a stimulus, it is expected that mast cell acti-
vation was even further increased earlier after application 
of LPA . Cromolyn treatment prevented the LPA-induced 
mast cell activation (38 ± 8% activated mast cells). Perivas-
cular and intimal neutrophil numbers were unaltered after 
LPA challenge (data not shown). Interestingly, plaque 
macrophage content was seen to be enhanced upon LPA 
treatment (15.8 ± 2.7% vs. 9.6 ± 2.0% in control animals, 
 P < 0.05,  Fig. 4A ), and this effect did not occur in cromolyn-
treated mice (7.2 ± 1.3%,  P < 0.01 vs. LPA) suggesting that 
the macrophage accumulation at least in part resulted 
from mast cell activation. This may possibly be caused by 
the LPA-mediated release of MCP-1 as shown in vitro. Fur-
thermore, as LPA has been reported to promote mac-
rophage survival ( 28 ), we examined the direct effect of 
LPA on a murine macrophage cell line. We show here that 
LPA induced a dose-dependent proliferative response in 
RAW 264.7 murine macrophages ( Fig. 4B ). No differences 
were seen with respect to elastic lamina breaks between 
in C57Bl/6 mice; PBS: 1.0 ± 0.12 vs. LPA: 1.08 ± 0.14 in 
Kit(W   sh /W   sh ) mice] and that of   -hexosaminidase [PBS: 
1.0 ± 0.05 vs. LPA: 1.25 ± 0.15 in C57Bl/6 mice; PBS: 1.0 ± 
0.55 vs. LPA: 0.99 ± 0.16 in Kit(W   sh /W   sh ) mice], all dis-
played as fold change compared with PBS. Taken together, 
these data demonstrate that LPA is a potent inducer of 
LPA 1 -dependent mast cell activation, and in particular of 
tryptase and MCP-1 release. 
 Microvascular leakage in vivo 
 Mast cells are potent inducers of vascular leakage, which 
induces plaque destabilization as shown previously ( 6 ). To 
determine whether LPA-mediated mast cell activation en-
hances vascular leakage, we injected LPA and LPA-acti-
vated mast cells intradermally and quantifi ed leakage with 
Evans Blue dye. LPA and compound 48/80 per se were 
already seen to induce vascular leakage ( Fig. 2B ,  P < 0.05 
and  P < 0.001, respectively), due to activation of resident 
dermal mast cells as demonstrated previously ( 6 ). MC/9 
cells without stimulus also induced vascular leakage, possi-
bly due to shear stress-induced activation during injection. 
We observed that intradermal injection of LPA-activated 
MC/9 cells highly and signifi cantly induced vascular leak-
age ( P < 0.001 compared with PBS control,  P < 0.05 com-
pared with MC/9 only,  Fig. 2B ) similarly as the positive 
control, compound 48/80 activated mast cells ( P < 0.001 
compared with PBS ). Intradermal MC/9 injection in mast 
cell defi cient Kit(W   sh /W   sh ) mice unequivocally showed 
that compound 48/80 and LPA induced massive and per-
sistent activation of transferred mast cells in skin ( Fig. 2C , 
 P < 0.01 and  P < 0.05, respectively, compared with unstim-
ulated MC/9 cells). These data further establish that LPA 
is a potent mast cell activator which may affect atheroscle-
rotic plaque stability in vivo. 
 Local LPA treatment and plaque morphology 
 We and others have previously demonstrated that LPA 
progressively accumulates in plaques during disease progres-
sion ( 20, 21 ) and we here confi rmed the presence and ac-
tual location of a range of LPA species in the atherosclerotic 
 Fig.  3. Adventitial mast cell content of atherosclerotic carotid artery lesions after focal LPA administration. A: 
Plaque size is not changed at three days after local LPA challenge as compared with control mice or mice that 
had received the mast cell stabilizer cromolyn. B: Total adventitial mast cell contents of control, LPA-treated, 
and LPA/cromolyn-treated mice were essentially similar. C: Adventitial mast cell degranulation was increased 
at three days after local LPA challenge as compared with control mice (* P < 0.05). Cromolyn treatment 
normalized the levels of mast cell activation in the LPA-challenged animals. 
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challenge did not enhance the incidence of intraplaque 
hemorrhage and hemosiderin deposits in lesions in cro-
molyn-treated mice as these showed comparable numbers 
to the control group (20%,  Fig. 4C ). Perl’s iron staining 
confi rmed these fi ndings: 7 of 23 (35%) iron positive 
plaques in the LPA group compared with 2 of 20 (10%) in 
the control group ( Figs. 4D ). 
 To elucidate whether the observed effects of LPA in vivo 
are mast cell dependent, we challenged mast cell-defi cient 
apoE   /   Kit(W   sh /W   sh ) mice locally with LPA. LPA chal-
lenge did not affect lesion size and any other morphomet-
ric parameters in apoE   /   Kit(W   sh /W   sh ) mice (controls: 
125 ± 20 × 10 3   m 2 vs. LPA: 144 ± 14 × 10 3   m 2 ,  Fig. 5A ). 
We did not observe signifi cant effects on intimal mac-
rophage accumulation between the controls and LPA 
treated apoE   /   Kit(W   sh /W   sh ) mice ( Fig. 5B ). Mac-
rophage content of the apoE   /   Kit(W   sh /W   sh ) mice was 
in general lower as compared with apoE   /   mice. Interest-
ingly, LPA did not enhance the incidence of intraplaque 
hemorrhages in apoE   /   Kit(W   sh /W   sh ) (0 of 14,  P = 0.01 
compared with LPA treatment in apoE   /   mice,  Fig. 5C ), 
groups (LPA: 2.1 ± 0.6 vs. 1.8 ± 0.5 in control animals and 
1.4 ± 0.3 in LPA/cromolyn animals). Adventitial and 
in vitro mast cell degranulation was previously reported 
to promote apoptosis of vascular smooth muscle cells, 
endothelial cells, and macrophages ( 6, 29 ). TUNEL stain-
ing, however, did not reveal any differences in the rate of 
intimal apoptosis three days after LPA challenge (1.5 ± 
0.4% TUNEL positive nuclei vs. 1.2 ± 0.3% in the controls 
and 2.2 ± 0.6% in LPA/cromolyn animals). In addition, 
necrotic core size did not differ between the groups (data 
not shown). In vitro, LPA was not able to rescue mac-
rophages from tryptase-induced apoptosis, suggesting that 
mast cell-induced apoptosis was compensated for by de 
novo infl ux of leukocytes, and possibly mediated by mast 
cell-derived MCP-1 (supplementary Fig. IV ). 
 Interestingly, LPA-challenged plaques demonstrated 
the presence of intraplaque hemorrhages characterized 
by accumulation of intimal erythrocytes in 45% of the 
plaques in LPA-challenged animals (10 of 23,  Fig. 4C ), 
while intraplaque hemorrhage was observed in only 20% 
of the plaques in control mice (4 of 20,  Fig. 4C ). The LPA 
 Fig.  4. Effects of LPA on macrophages and hemorrhage. A: Intimal macrophage content in control, LPA-treated, and LPA/cromolyn-
treated animals. Intimal macrophage content signifi cantly increased in the LPA-treated group, an effect that was prevented by cromolyn 
treatment. The right panels are representative MOMA-2 stained cryosections of control (upper panel), LPA-treated (middle panel), and 
LPA/cromolyn-treated animals (lower panel ); * P < 0.05 compared to control;  ##  P < 0.01 compared to LPA. B: Effect of LPA on murine RAW 
264.7 proliferation. A dose-dependent increase in proliferation is seen in RAW 264.7 murine macrophages. ** P < 0.01, *** P < 0.001 versus 
untreated cells (control). C: Quantifi cation of the number of plaques containing intraplaque hemorrhages in control, LPA-treated, and 
LPA/cromolyn-treated animals suggesting an increased frequency of hemorrhages after LPA challenge. Cromolyn treatment normalized 
the increase in intraplaque hemorrhage in LPA-challenged animals. A representative hematoxylin/eosin stained cryosection of a plaque 
from an LPA-challenged mouse is displayed on the right demonstrating intraplaque hemorrhages and erythrocyte extravasation (arrows) 
in the intima. D: Quantifi cation of the number of Perl’s iron positive plaques in control, LPA-treated, and LPA/cromolyn-treated animals 
suggesting an increased frequency of iron deposits after LPA treatment. Cromolyn treatment normalized the frequency of plaques with 
iron deposits. On the right is a representative Perl’s iron staining revealing large areas with iron deposits (arrows). 
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plaque apoptosis was not altered upon LPA challenge, 
despite the preferential secretion of tryptase, previously 
shown by us and others ( 6, 33 ) as main culprit in mast cell-
associated apoptosis. Possibly the pro-apoptotic effects of 
the mast cell secretome are counteracted by the intrinsic 
histone deacetylase and serine threonine kinase (Akt)-
dependent anti-apoptotic effects of LPA itself ( 27, 34 ). 
However, in our in vitro studies LPA was not able to rescue 
macrophages from tryptase induced apoptosis, rendering 
this theory unlikely. Hypothetically, LPA may also lower 
the capacity of monocyte-derived cells to emigrate from 
the vessel wall ( 35 ). LPA elicited effects on macrophage 
content were however completely abolished by cromolyn 
treatment, which was previously demonstrated to mainly 
target mast cells without any side effects on other cell types 
such as neutrophils and macrophages at the dosage used 
in our animal model ( 6 ). It is conceivable that chemotac-
tic effects exerted by LPA-activated mast cells outbalance 
the aforementioned intrinsic LPA effects. It has already 
been demonstrated that murine mast cells release a plethora 
of chemokines including the CXCR2 ligand KC which can 
trigger directly and indirectly, via very late antigen-4 ( 36 ), 
leukocyte arrest to the endothelium. Furthermore, we now 
demonstrate that LPA favors mast cell release of MCP-1, 
which has long since been recognized as one of the primary 
cytokines in monocyte recruitment to the plaque ( 37 ). We 
thus hypothesize that mast cell degranulation promotes 
monocyte recruitment, while LPA on its own account will 
prolong their life span and inhibit their emigration, thereby 
increasing the plaque macrophage content. Mast cell stabi-
lization by cromolyn possibly reverses this increase by pre-
venting the fi rst step of monocyte recruitment and adhesion. 
 A few limitations of the study are worth mentioning. 
First, LPA is a rather heterogeneous class of monoacylated 
phospholipids that can impact a range of processes besides 
mast cell function. However, LPA-induced phenotypic 
which suggests that LPA induces intraplaque hemorrhage 
via a mast cell-dependent mechanism. 
 DISCUSSION 
 Activated mast cells were shown to accumulate in the 
arterial adventitia and intima during plaque progression 
and to promote plaque progression and plaque destabili-
zation ( 4–6 ). Oxidized LDL has been proposed as the en-
dogenous stimulus that may be responsible for mast cell 
activation in atherosclerosis ( 15, 16 ). One of oxLDL’s 
main lipid constituents, LPA, has a wide range of effects 
on mast cells, infl uencing processes such as proliferation, 
differentiation, and release of histamine, macrophage in-
fl ammatory protein-1  , IL-8, eotaxin, and MCP-1 ( 18, 19 ). 
Moreover, as this bioactive lipid progressively accumulates 
in plaques during disease progression ( 20, 21 ), it may be a 
likely candidate for vascular mast cell activation in the con-
text of atherosclerosis. 
 Concordant with our earlier fi ndings, we were able to 
detect several LPA species in mouse plaques, in particular 
in the intimal lipid core of the plaque underlying the 
fi brous cap of the lesion. Our in vitro and in vivo experi-
ments not only confi rm that LPA is able to induce mast 
cell activation but also demonstrate that the secretion pat-
tern after LPA challenge, with preferential release of 
tryptase over   -hexosaminidase and chymase, differs from 
that of other stimuli such as compound 48/80, indicating 
that different activators have different mast cell releasate 
profiles. In addition, we demonstrate here that LPA-
induced mast cell activation enhances microvascular 
leakage, allowing the infl ux of detrimental agents and 
hematopoietic cell subsets such as monocytes and erythro-
cytes into the atherosclerotic plaque. 
 One of the features of LPA treatment indeed appeared to 
be the acute increase in intraplaque hemorrhage incidence, 
a phenomenon that was also observed after dinitrophenyl 
hapten-elicited mast cell activation in situ ( 6 ). Intraplaque 
hemorrhage is a potent pro-atherogenic stimulus and risk 
factor in plaque destabilization, as it is accompanied by de-
position of erythrocyte-associated cholesterol and enlarge-
ment of the necrotic core of the atherosclerotic plaque. 
Treatment of mice with cromolyn during LPA challenge, 
similarly as after dinitrophenyl hapten challenge ( 6 ), normal-
ized the extent of mast cell degranulation in the adventitia, 
while largely preventing intraplaque hemorrhage, imply-
ing that mast cells are directly involved in LPA-mediated 
plaque destabilization . 
 During the development of atherosclerosis, tissue con-
centrations of LPA increase ( 21 ), thus enhancing local 
bioavailability of LPA with the capacity to destabilize 
plaques. Apoptosis at later stages of disease progression is 
considered deleterious for plaque stability ( 30 ). As mast 
cell degranulation was reported to promote apoptosis of 
smooth muscle cells ( 31, 32 ), endothelial cells ( 29 ), and 
intimal macrophages ( 6 ), we established the intimal apop-
totic nuclei content after LPA challenge. To our surprise, 
 Fig.  5. LPA in mast cell-defi cient apoE   /   Kit(W   sh /W   sh ) mice. 
A: LPA did not affect lesion size in apoE   /   Kit(W   sh /W   sh ) mice, 
while also intimal macrophage content was not signifi cantly 
changed after LPA challenge (B ). C: LPA did not elicit any intra-
plaque hemorrhages in the mast cell-defi cient apoE   /   Kit(W   sh /
W   sh ) mice ( P < 0.05 as compared with LPA treatment in apoE   /   
mice), suggesting that LPA induces intraplaque hemorrhage in a 
mast cell-dependent fashion. 
 at W
alaeus Library / B
IN












Supplemental Material can be found at:
Lysophosphatidic acid induces plaque destabilization 1273
  7 .  Sun ,  J. ,  G. K.  Sukhova ,  P. J.  Wolters ,  L. A.  MacFarlane ,  P.  Libby ,  C. 
 Sun ,  Y.  Zhang ,  J.  Liu ,  T. L.  Ennis ,  R.  Knispel ,  et al .  2007 .  Mast cells 
promote atherosclerosis by releasing proinfl ammatory cytokines. 
 Nat. Med.  13 :  719 – 724 . 
  8 .  Healicon ,  R. M. , and J. C. Foreman.  1985 .  Rat mast cell activation 
and inactivation: differences when various ligands are used to in-
duce secretion.  Agents Actions .  16 :  155 – 159 . 
  9 .  Bot ,  I. , S. C. de Jager, M. Bot, S. H. van Heiningen, P. de Groot, 
R. W. Veldhuizen, T. J. van Berkel, J. H. von der Thüsen, and 
E. A. Biessen.  2010 .  The neuropeptide substance P mediates adven-
titial mast cell activation and induces intraplaque hemorrhage in 
advanced atherosclerosis.  Circ. Res.  106 :  89 – 92 . 
 10 .  Johnson ,  A. R. ,  T. E.  Hugli , and  H. J.  Müller-Eberhard .  1975 . 
 Release of histamine from rat mast cells by the complement pep-
tides C3a and C5a.  Immunology .  28 :  1067 – 1080 . 
 11 .  Wang ,  J. ,  X.  Cheng ,  M. X.  Xiang ,  M.  Alanne-Kinnunen ,  J. A.  Wang , 
 H.  Chen ,  A.  He ,  X.  Sun ,  Y.  Lin ,  T. T.  Tang , et al.  2011 .  IgE stimu-
lates human and mouse arterial cell apoptosis and cytokine expres-
sion and promotes atherogenesis in Apoe  /  mice.  J. Clin. Invest. 
 121 :  3564 – 3577 . 
 12 .  Lappalainen ,  J. ,  K. A.  Lindstedt ,  R.  Oksjoki , and  P. T.  Kovanen . 
 2011 .  OxLDL-IgG immune complexes induce expression and se-
cretion of proatherogenic cytokines by cultured human mast cells. 
 Atherosclerosis .  214 :  357 – 363 . 
 13 .  Laine ,  P. ,  A.  Naukkarinen ,  L.  Heikkilä ,  A.  Penttilä , and  P. T. 
 Kovanen .  2000 .  Adventitial mast cells connect with sensory 
nerve fi bers in atherosclerotic coronary arteries.  Circulation .  101 : 
 1665 – 1669 . 
 14 .  Oksjoki ,  R. ,  P.  Laine ,  S.  Helske ,  P.  Vehmaan-Kreula ,  M. I. 
 Mäyränpää ,  P.  Gasque , P.T. Kovanen, and M. O. Pentikäinen.  2007 . 
 Receptors for the anaphylatoxins C3a and C5a are expressed in 
human atherosclerotic coronary plaques.  Atherosclerosis .  195 :  90 – 99 . 
 15 .  Liao ,  L. , and  D. N.  Granger .  1996 .  Role of mast cells in oxidized 
low-density lipoprotein-induced microvascular dysfunction.  Am. J. 
Physiol.  271 :  H1795 – H1800 . 
 16 .  Kelley ,  J. ,  G.  Hemontolor ,  W.  Younis ,  C.  Li ,  G.  Krishnaswamy , and 
 D. S.  Chi .  2006 .  Mast cell activation by lipoproteins.  Methods Mol. 
Biol.  315 :  341 – 348 . 
 17 .  Hashimoto ,  T. ,  H.  Ohata , and  K.  Honda .  2006 .  Lysophosphatidic 
acid induces plasma exudation and histamine release in mice via 
lysophosphatidic acid receptors.  J. Pharmacol. Sci.  100 :  82 – 87 . 
 18 .  Bagga ,  S. ,  K. S.  Price ,  D. A.  Lin ,  D. S.  Friend ,  K. F.  Austen , and  J. A. 
 Boyce .  2004 .  Lysophosphatidic acid accelerates the development of 
human mast cells.  Blood .  104 :  4080 – 4087 . 
 19 .  Lin ,  D. A. , and  J. A.  Boyce .  2005 .  IL-4 regulates MEK expression 
required for lysophophatidic acid-mediated chemokine generation 
by human mast cells.  J. Immunol.  175 :  5430 – 5438 . 
 20 .  Siess ,  W. ,  K. J.  Zangl ,  M.  Essler ,  M.  Bauer ,  R.  Brandl ,  C.  Corrinth , 
 R.  Bittman ,  G.  Tigyi , and  M.  Aepfelbacher .  1999 .  Lysophosphatidic 
acid mediates the rapid activation of platelets and endothelial 
cells by mildly oxidized low density lipoprotein and accumulates 
in human atherosclerotic lesions.  Proc. Natl. Acad. Sci. USA .  96 : 
 6931 – 6936 . 
 21 .  Bot ,  M. ,  I.  Bot ,  R.  Lopez-Vales ,  C. H.  van de Lest ,  J. S.  Saulnier-
Blache ,  J. B.  Helms ,  S.  David ,  T. J. C.  van Berkel , and  E. A. L. 
 Biessen .  2010 .  Atherosclerotic lesion progression changes lysophos-
phatidic acid homeostasis to favor its accumulation.  Am. J. Pathol. 
 176 :  3073 – 3084 . 
 22 .  Cui ,  M. Z.  2011 .  Lysophosphatidic acid effects on atherosclerosis 
and thrombosis.  Clin. Lipidol.  6 :  413 – 426 . 
 23 .  Rizza ,  C. ,  N.  Leitinger ,  J.  Yue , D. J. Fischer, D. A. Wang, P. T. Shih, 
H. Lee, G. Tigyi, and J. A. Berliner.  1999 .  Lysophosphatidic acid 
as a regulator of endothelial/leukocyte interaction.  Lab. Invest.  79 : 
 1227 – 1235 . 
 24 .  Zhou ,  Z. ,  P.  Subramanian ,  G.  Sevilmis ,  B.  Globke ,  O.  Soehnlein , 
 E.  Karshovska ,  R.  Megens ,  K.  Heyll , J. Chun, J. S. Saulnier-Blache, et al. 
 2011 .  Lipoprotein-derived lysophosphatidic acid promotes athero-
sclerosis by releasing CXCL1 from the endothelium.  Cell Metab.  13 : 
 592 – 600 . 
 25 .  von der Thüsen ,  J. H. ,  T. J. C.  van Berkel , and  E. A. L.  Biessen . 
 2001 .  Induction of rapid atherogenesis by perivascular carotid col-
lar placement in apolipoprotein E-defi cient and low-density lipo-
protein receptor-defi cient mice.  Circulation .  103 :  1164 – 1170 . 
 26 .  Altelaar ,  A. F. ,  I.  Klinkert ,  K.  Jalink ,  R. P.  de Lange ,  R. A.  Adan , 
 R. M.  Heeren , and  S. R.  Piersma .  2006 .  Gold-enhanced biomolecu-
lar surface imaging of cells and tissue by SIMS and MALDI mass 
spectrometry.  Anal. Chem.  78 :  734 – 742 . 
changes in the plaque observed in this study did not occur 
after treatment with the mast cell stabilizer cromolyn and 
in mast cell defi cient apoE   /   Kit(W   sh /W   sh ) mice which 
suggests that in this experimental setup the mast cell is a 
prominent mediator of the LPA-induced plaque destabili-
zation. Second, the LPA dose used in this study may far 
exceed endogenously available LPA levels, leading to non-
physiological responses. In previous studies however, we 
demonstrated that in advanced lesions the level of LPA is 
approximately 40 pmol/mg atherosclerotic tissue, which 
corresponds to approximately 35 ng of LPA per plaque. In 
this study, we locally applied 92 ng of LPA in a pluronic gel 
that releases its content within three days, which suggests 
that the dose of LPA used is within a physiological range. 
Third, in this study we topically applied 18:1 LPA, while in 
plaque a number of polyunsaturated LPA species were 
found to accumulate. The latter were shown to display an 
even higher potency in, for example, platelet activation 
( 38 ) and this may also hold true for mast cell activation. 
However, 18:1 LPA is one of the most abundant LPA spe-
cies in plaque, rendering it highly likely that it is directly 
accessible for plaque mast cells. 
 In conclusion, we here provide in vivo proof that LPA 
bioavailability in the plaque is an important factor in ath-
erosclerotic plaque stability and that effects of LPA are at 
least partly mediated by LPA-induced mast cell activation. 
Moreover, we show that enhanced LPA levels in or close to 
the plaque, as occurring during plaque progression, will 
increase the plaque macrophage content and induce vas-
cular leakage in a mast cell-dependent manner. LPA has 
previously been shown to have a number of thrombogenic 
and atherogenic actions as also recently reviewed by Schober 
and Siess ( 39 ) and these data provide yet another mecha-
nism by which LPA may affect atherosclerotic plaque pro-
gression and destabilization. We propose that intervention 
in LPA bioavailability or activity in the plaque may be an 
effective measure to reduce mast cell activation and vascu-
lar infl ammation, improve plaque stability, and concomi-
tantly reduce plaque thrombogenicity, and thus could well 
represent an effective therapeutic strategy in the preven-
tion of acute coronary syndromes.  
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